Angiogenesis inhibitor approved as part of combination therapy for first-line treatment of nonsquamous NSCLC
Avastin
BevacizumabGENENTECHAngiogenesis inhibitor approved as part of combination therapy for first-line treatment of nonsquamous NSCLC
This monoclonal antibody binds human vascular endothelial growth factor (VEGF), preventing VEGF from binding with its receptors. The inhibition of binding prevents the proliferation of endothelial cells and the formation of new blood vessels, and this angiogenesis inhibition slows microvascular growth and metastatic progression. Bevacizumab, in combination with carboplatin and paclitaxel, was approved on October 12, 2006, for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic nonsquamous, non-small cell lung cancer (NSCLC). Bevacizumab was previously approved as part of combination therapy for the treatment of patients with metastatic carcinoma of the colon or rectum.
Safety. Cases of gastrointestinal perforations with associated fistula formation or intra-abdominal abscesses have been reported; some cases have been fatal. In patients with gastrointestinal perforation, bevacizumab should be permanently discontinued. Bevacizumab therapy can lead to complications in wound healing, including wound dehiscence. Patients should not begin treatment with bevacizumab until ≥28 days have elapsed since major surgery and surgical incisions have fully healed. Patients treated with bevacizumab have experienced both minor hemorrhages and serious, sometimes fatal, hemorrhagic events. In patients with serious hemorrhage, bevacizumab therapy should be discontinued. Bevacizumab therapy may lead to arterial thromboembolic events, including cerebral infarction, transient ischemic attacks, myocardial infarction, and angina. Severe hypertension also has been reported among patients treated with bevacizumab. Bevacizumab therapy has been associated with severe neutropenia, febrile neutropenia, proteinuria, reversible posterior leukoencephalopathy syndrome, and congestive heart failure. Infusion reactions reported in clinical trials include hypertension, hypertensive crises, wheezing, oxygen desaturation, hypersensitivity, chest pain, headaches, rigors, and diaphoresis. The most common adverse events associated with bevacizumab treatment include asthenia, pain, abdominal pain, headache, hypertension, diarrhea, nausea, vomiting, anorexia, stomatitis, constipation, upper respiratory infection, epistaxis, dyspnea, exfoliative dermatitis, and proteinuria.
Dosing. The recommended dose of bevacizumab is 15 mg/kg as an intravenous infusion every 3 weeks. The initial dose should be delivered over 90 minutes, with the infusion time dropping to 60 minutes and then to 30 minutes at subsequent infusions if the infusion time is well tolerated.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.